Germany's Boehringer, Indian pharma in legal battle over diabetes drug

The German drug maker has obtained interim injunctions against MSN Labs and Dr Reddy's Lab

German drugmaker Boehringer Ingelheim (BI) has obtained two separate interim injunctions against two Indian drugmakers – MSN Laboratories and Dr Reddy’s Laboratories – who launched cheaper, generic versions of their anti-diabetic drug empagliflozin.

BI holds a patent for Empagliflozin under the name Jardiance in India till 2025, the company said.

A Boehringer Ingelheim India spokesperson said that it has obtained two separate orders granting ad-interim injunction that restrains the two domestic pharmaceutical manufacturers from ‘launching, making, using, offering for sale, selling, importing and/ or exporting their respective generic version of Empagliflozin drugs’.

“Boehringer Ingelheim holds a valid patent for Empagliflozin